美国东部时间2022年4月27日上午10点，2022美国临床肿瘤学会（ASCO）年会日程公布。今年的消化道肿瘤领域Oral Abstact Session划分为【胃食管与肝胆胰肿瘤】、【结直肠与肛门肿瘤】两个专场，【肿瘤资讯】还特此精选了Clinical Science Symposium部分。让我们一起来看看都有哪些精彩预告吧！
胃食管与肝胆胰肿瘤专场
日期： 2022年6月5日周日|21:00开始（北京时间）
会议主席：
Katrina Sophia Pedersen, MD, MS, Washington University School of Medicine in St. Louis；
Mary Uan-Sian Feng, MD, UCSF Helen Diller Family Comprehensive Cancer Center
1. 来自K-Umbrella胃癌研究的第一份报告：一项晚期胃癌 (AGC)二线治疗的开放标签、多中心、随机、生物标志物整合试验
The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).
摘要号：4001
第一作者：Sun Young Rha, MD, PhD
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
2. DANTE中期结果，一项在FLOT-AIO德国胃癌组和瑞士SAKK进行的随机、多中心、IIb期试验：围手术期阿替利珠单抗联合FLOT化疗对比单独使用FLOT治疗在可切除食管胃腺癌患者的手术和病理结果以及病理退缩
Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK
摘要号：4003
第一作者：Salah-Eddin Al-Batran, MD
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt Am Main, Germany and Krankenhaus Nordwest, University Cancer Center Frankfurt
3. 替莫唑胺单药 vs. 替莫唑胺+卡培他滨治疗晚期胰腺神经内分泌瘤患者的随机研究(ECOG-ACRIN E2211) ：疗效最终分析以及MGMT作为预测性生物标志物的评估
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).
摘要号：4004
第一作者：Pamela L. Kunz, MD
Yale Cancer Center, Yale School of Medicine
4．NET-02：伊立替康脂质体注射液 (nal-IRI) 和 5-氟尿嘧啶 (5-FU)/亚叶酸或多西他赛作为疾病进展的低分化肺外神经内分泌癌（PD-EP-NEC）患者二线治疗的多中心、随机 II 期试验
NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
摘要号：4005
第一作者：Mairead Geraldine McNamara, PhD,
MBBCh, BSc University of Manchester
5．研究者发起的多中心II期研究（HERB试验）：Trastuzumab deruxtecan (T-DXd; DS-8201) 用于HER2表达不可切除性/复发性胆道癌 (BTC) 患者
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)
摘要号：4006
第一作者：Akihiro Ohba, MD，National Cancer Center Hospital
6．前瞻性全国性GERCOR 随机试验结果：晚期胰腺癌 (APACaP)患者的适应性体力活动
Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.
摘要号：4007
第一作者：Cindy Neuzillet, MD
Department of Medical Oncology, Institut Curie-Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University
7. CONKO-007 试验的首次结果：不可切除局部晚期胰腺癌患者诱导化疗后接受放化疗 vs. 单独化疗的随机III期试验
Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
摘要号：4008
第一作者：Rainer Fietkau, MD
Department of Radiation Oncology, Universitatsklinikum Erlangen, Friedrich-Alexander-Universitat Erlangen-Nürnberg
8. SEQUENCE试验：白蛋白结合型紫杉醇/吉西他滨序贯改良FOLFOX治疗一线转移性胰腺癌
Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: The SEQUENCE trial
摘要号：4022
第一作者：Alfredo Carrato, MD, PhD，IRYCIS, CIBERONC, Alcalá University, Hospital Universitario Ramón y Cajal
结直肠癌和肛门癌专场
日期：2022年6月6日周一 | 22:45开始（北京时间）
会议主席：
Michael Cecchini, MD, Yale University School of Medicine ； Christine Marie Walko, PharmD, FCCP, BCOP, Moffitt Cancer Center
1.mFOLFOX6或CAPOX用于局部晚期结肠癌患者的围手术期化疗 (OPTICAL)：一项多中心、随机、III 期试验
Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.
摘要号：3500
第一作者：胡华斌，MD，中山大学附属第六医院
2. TAUTEM 研究的术前、术中及病理学结果：新辅助治疗后局部切除 (TEM)对比全直肠系膜切除 (TME) 在T2~T3s、N0、M0 (T2T3sN0M0)直肠癌的非劣效性多中心前瞻性随机对照研究
Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study.
摘要号：3501
第一作者：Xavier Serra-Aracil，Corporacion Sanitaria Parc Tauli
3. STAR-TREC II 期：对于早期直肠癌，我们可以通过观察等待或经肛门手术后（化）放疗 vs 全直肠系膜切除术来保留直肠吗？
STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?
摘要号：3502
第一作者：Simon Parkinson Bach, MD，FRCS
University of Birmingham
4. IMPROVE 研究:随机间歇或连续帕尼单抗+FOLFIRI (FOLFIRI/PANI) 用于 RAS/BRAF 野生型 (wt) 转移性结直肠癌 (mCRC) 患者的一线治疗
Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
摘要号：3503
第一作者：Antonio Avallone, MD，Istituto Nazionale Tumori Fondazione G. Pascale
5. STRATEGIC-1：不可切除的KRAS/NRAS/BRAF野生型转移性结直肠癌的多线治疗——一项GERCOR-PRODIGE 随机开放标签III期研究
STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.
摘要号：3504
第一作者：Benoist Chibaudel, MD，Department of Medical Oncology, Franco-British Institute
6. GONO的III 期随机TRIPLETE 研究结果：改良 FOLFOXIRI+帕尼单抗 (mFOLFOXIRI/PAN)对比mFOLFOX6/PAN作为不可切除的RAS和BRAF野生型转移性结直肠癌 (mCRC) 患者的初始治疗
Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.
摘要号：3505
第一作者：Chiara Cremolini, MD, PhD
Department of Translational Research and New Technologies in Medicine and Surgery-Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana
7. 荷兰结直肠癌组的III期CAIRO5研究：FOLFOXIRI+贝伐珠单抗 vs. FOLFOX/FOLFIRI+贝伐珠单抗用于初始不可切除的结直肠癌肝转移(CRLM)且原发肿瘤在右侧和/或RAS/BRAFV600E突变患者的一线治疗
FOLFOXIRI + bevacizumab versus FOLFOX/ FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
摘要号：3506
第一作者：Cornelis J. A. Punt, PhD, MD
University Medical Center Utrecht
8. 转移灶不可切除的同时性转移结直肠癌在系统治疗前原发灶切除 vs 不切除的随机临床试验
Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases.
摘要号：3507
第一作者：Nuh N. Rahbari
Universityhospital Mannheim, University of Heidelberg, Medical Faculty Mannheim
9. SCARCE-PRODIGE 60 随机 II 期研究：阿替利珠单抗加改良DCF（多西他赛、顺铂和 5-氟尿嘧啶）作为转移性或局部晚期肛门鳞癌的一线治疗
Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.
摘要号：3508
第一作者：Stefano Kim, MD
Bourgogne-Franche Comté University, Department of Medical Oncology, Besançon University Hospital
胃食管与肝胆胰肿瘤专场
日期：2022年6月4日周六 | 05:30-07:00（北京时间）
大会主席：
E. Gabriela Chiorean, MD, University of Washington, Fred Hutchinson Cancer Research Center；
Rachna T. Shroff, MD, University of Arizona Cancer Center
1. FOENIX-CCA2 试验的更新结果：futibatinib 在含有FGFR2融合/重排的肝内胆管癌 (iCCA) 中的疗效和安全性
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
摘要号：4009
讲者: Lipika Goyal, MD，Mass General Cancer Center, Harvard Medical School
2. 转移性胰腺癌患者的随机、三臂 II 期研究：独特的生物学标签与化学免疫治疗后的存活率相关
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
摘要号：4010
讲者: Lacey J. Kitch, PhD，Parker Institute for Cancer Immunotherapy
3. 尼妥珠单抗联合吉西他滨对比吉西他滨治疗 K-RAS 野生型局部晚期或转移性胰腺癌：一项前瞻性、随机对照、双盲、多中心、 III 期临床试验
Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.
摘要号: LBA4011
讲者: 秦叔逵，MD，南京金陵医院肿瘤中心
日期：2022年6月6日 周一|02:05开始（北京时间）
帕尼单抗 (PAN) + mFOLFOX6 vs 贝伐珠单抗(BEV) + mFOLFOX6 作为RAS野生型 (WT) 转移性结直肠癌 (mCRC)患者的一线治疗：III期 PARADIGM 试验的结果
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
摘要号: LBA1
讲者: Takayuki Yoshino, PhD, MD，National Cancer Center Hospital East
https://conferences.asco.org/am/attend
排版编辑：肿瘤资讯-Bree
苏公网安备 32059002004080号
